DehydraTECH, NCT06648031: Comparison of the Safety, Efficacy and Pharmacokinetics of -CBD and -GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants |
|
|
| Not yet recruiting | 1 | 80 | RoW | Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide, Arm 4 - Rybelsus medication (semaglutide) alone | Lexaria Bioscience Corp. | Type2diabetes | 05/25 | 09/25 | | |
